Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2658-2665

  Nguyen, Nga ^b   Kuliopulos, Athan ^b   Graham, Roger A ^b   Covic, Lidija ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; INTERSTITIAL COLLAGENASE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MIGRATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA;

ANIMALS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; ENZYME INDUCTION; FIBROBLASTS; GENE SILENCING; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 1; MICE; NIH 3T3 CELLS; RECEPTOR, PAR-1; STROMAL CELLS;

EID: 33645085566     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2082     Document Type: Article

References (39)

1. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005;11:481-3.
2. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
3. Migita T, Sato E, Saito K, et al. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int J Cancer 1999;84:74-9.
4. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloprotease family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
5. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13.
6. Arribas J. Matrix metalloproteases and tumor invasion. N Engl J Med 2005;352:2020-1.
7. Whitehead I, Kirk H, Kay R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol Cell Biol 1995;15:704-10.
8. Martin CB, Mahon GM, Klinger MB, et al. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001;20:1953-63.
9. Yin Y-J, Salah Z, Maoz M, et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J 2003;17:163-74.
10. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14.
11. Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002;19:181-9.
12. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92:3694-700.
13. 5 integrin. J Biol Chem 2001;276:10952-62.
14. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis in vivo. Cancer Res 1992;52:3267-72.
15. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003;22:3130-7.
16. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2α results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003;278:46632-42.
17. Hazarika P, McCarty MF, Prieto VG, et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 2004;64:7361-9.
18. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-75.
19. Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001;61:5933-40.
20. Chen C-C, Chen N, Lau LF. The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 2001;276:10443-52.
21. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
22. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1β by matrix metalloproteinases. J Biol Chem 1996;271:14657-60.
23. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000;60:5603-7.
24. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998;95:6355-60.
25. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993;26:125-30.
26. Xie D, Miller CW, O'Kelly J, et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001;276:14187-94.
27. Walter-Yohrling J, Pratt BM, Ledbetter S, Teicher BA. Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model. Cancer Chemother Pharmacol 2003;52:263-9.
28. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and β-catenin-TCF/Lef signaling pathways. Cancer Res 2004;64:1987-96.
29. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999;38:4572-85.
30. Reiter LA, Rizzi JP, Pandit J, et al. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg Med Chem Lett 1999;9:127-32.
31. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem 1996;39:4879-87.
32. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A 1999;96:12257-62.
33. Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17β-estradiol and overexpression in human breast cancer. Endocrinology 2001;142:2540-8.
34. Muramatsu Y, Tsujie M, Kohda Y, et al. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002;62:1601-10.
35. Kireeva ML, Mo FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-34.
36. Yang GP, Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991;2:351-7.
37. Davies B, Miles DW, Happerfield LC. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
38. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
39. Pendurthi UR, Allen KE, Ezban M, Rao VM. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa tissue factor-induced signal transduction. J Biol Chem 2000;275:14632-41.